Can a Two-Drug cocktail shrink Hard-to-Treat bile duct cancers?
NCT ID NCT07729033
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial is testing whether a combination of two drugs—sacituzumab tirumotecan and envafolimab—can shrink advanced biliary tract cancers (cancers of the bile ducts or gallbladder) that have grown despite initial treatment. The study enrolls up to 28 adults whose tumors carry a protein called TROP2. Participants receive the drugs intravenously and under the skin every two weeks for three cycles, with further treatment decided by their doctor. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab tirumotecan combined with envafolimab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced biliary tract cancers who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The combination may cause significant side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300308, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.